# A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma

> **NCT05577416** · EARLY_PHASE1 · COMPLETED · sponsor: **Melbourne Health** · enrollment: 14 (actual)

## Conditions studied

- Glioma

## Interventions

- **PROCEDURE:** Biopsy
- **DRUG:** Part A: Safusidenib Erbumine
- **PROCEDURE:** Surgery (maximal resection)
- **DRUG:** Part B: Safusidenib Erbumine

## Key facts

- **NCT ID:** NCT05577416
- **Lead sponsor:** Melbourne Health
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-11
- **Primary completion:** 2025-03-26
- **Final completion:** 2025-03-26
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05577416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05577416, "A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05577416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*